The scientific goals of the Experimental and Developmental (EDT) Program are to: 1) Discover and validate novel therapeutic targets;2) Identify new therapeutic agents and approaches, and 3) Conduct early phase translational clinical trials of novel therapies. The EDT Program is comprised of 25 members from two schools at the University of Texas Health Science Center at San Antonio (UTHSCSA) and one college at the University of Texas at San Antonio (UTSA). The EDT membership represents 11 departments and has been recruited from notable institutions including Harvard Medical School, MD Anderson Cancer Center and UT Southwestern. The EDT Program members have a wide range of expertise, from synthetic organic chemistry and structural biology, through lead identification and IND-enabling studies, obtaining an IND, to conducting clinical trials. These complementary areas of expertise provide the opportunities for cutting-edge translational research. Seven Program members are clinician scientists, physicians, or dentists who provide a strong translational focus to the program. The Co-Leaders, Drs. Weitman and Mooberry have complementary areas of expertise and interests to span the entire range of activities of the Program. In the past budget year, EDT members received a total of $2,150,045 of NCI funding (11 grants) and an additional $2,723,945 (15 grants) of other peer-reviewed cancer-related grant support. The EDT Program has 177 peer-reviewed cancer related publications of which 89 (50%) are intra-programmatic collaborations and 26 (15%) are inter-programmatic collaborations.
The Experimental and Developmental Therapeutics (EDT) Program takes the lead in the Cancer Therapy & Research Center's effort to develop and test new treatments for cancer. It is an integrated multidisciplinary collaborative effort between diverse disciplines of pre-clinical and clinical scientists, all of whom are focused on improving the treatment of cancer.
|Du, Liqin; Zhao, Zhenze; Suraokar, Milind et al. (2018) LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget 9:29601-29618|
|Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203|
|Sun, Xiujie; Gupta, Kshama; Wu, Bogang et al. (2018) Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice. J Biol Chem 293:2841-2849|
|Horning, Aaron M; Wang, Yao; Lin, Che-Kuang et al. (2018) Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response. Cancer Res 78:853-864|
|Gong, Siqi; Tomusange, Khamis; Kulkarni, Viraj et al. (2018) Anti-HIV IgM protects against mucosal SHIV transmission. AIDS 32:F5-F13|
|Gelfond, Jonathan; Goros, Martin; Hernandez, Brian et al. (2018) A System for an Accountable Data Analysis Process in R. R J 10:6-21|
|Soteros, Breeanne M; Cong, Qifei; Palmer, Christian R et al. (2018) Sociability and synapse subtype-specific defects in mice lacking SRPX2, a language-associated gene. PLoS One 13:e0199399|
|Katti, Sachin; Her, Bin; Srivastava, Atul K et al. (2018) High affinity interactions of Pb2+ with synaptotagmin I. Metallomics 10:1211-1222|
|De La Chapa, Jorge J; Singha, Prajjal Kanti; Lee, Debbie R et al. (2018) Thymol inhibits oral squamous cell carcinoma growth via mitochondria-mediated apoptosis. J Oral Pathol Med 47:674-682|
|Wang, Zhonghua; Bhattacharya, Akash; White, Tommy et al. (2018) Functionality of Redox-Active Cysteines Is Required for Restriction of Retroviral Replication by SAMHD1. Cell Rep 24:815-823|
Showing the most recent 10 out of 989 publications